| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anxiety Disorders | 61 | 2018 | 426 | 3.940 |
Why?
|
| Panic Disorder | 28 | 2009 | 121 | 3.670 |
Why?
|
| Panic | 57 | 1994 | 97 | 3.610 |
Why?
|
| Fear | 48 | 2006 | 239 | 2.760 |
Why?
|
| Phobic Disorders | 36 | 2003 | 227 | 2.650 |
Why?
|
| Olfactory Perception | 5 | 2018 | 20 | 1.870 |
Why?
|
| Sleep Wake Disorders | 9 | 2018 | 94 | 1.820 |
Why?
|
| Anxiety | 17 | 2021 | 422 | 1.450 |
Why?
|
| Carbamazepine | 38 | 2007 | 108 | 1.340 |
Why?
|
| Depressive Disorder | 55 | 2018 | 621 | 1.310 |
Why?
|
| Clonidine | 27 | 2003 | 66 | 1.260 |
Why?
|
| Sleep | 15 | 2018 | 263 | 1.200 |
Why?
|
| Agoraphobia | 21 | 2008 | 59 | 1.150 |
Why?
|
| Smell | 6 | 2022 | 131 | 1.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 9 | 2017 | 1506 | 1.070 |
Why?
|
| Arousal | 22 | 2003 | 168 | 1.060 |
Why?
|
| Growth Hormone | 18 | 1994 | 51 | 0.990 |
Why?
|
| Caffeine | 19 | 2005 | 81 | 0.990 |
Why?
|
| Odorants | 5 | 2021 | 52 | 0.980 |
Why?
|
| Adult | 138 | 2022 | 21403 | 0.970 |
Why?
|
| Bipolar Disorder | 35 | 2009 | 307 | 0.950 |
Why?
|
| Psychiatric Status Rating Scales | 28 | 2015 | 782 | 0.870 |
Why?
|
| Brain | 16 | 2017 | 2176 | 0.840 |
Why?
|
| Combat Disorders | 4 | 2017 | 102 | 0.790 |
Why?
|
| Hydrocortisone | 24 | 1997 | 291 | 0.790 |
Why?
|
| Female | 148 | 2022 | 38074 | 0.770 |
Why?
|
| Male | 145 | 2019 | 37321 | 0.750 |
Why?
|
| Humans | 206 | 2022 | 68618 | 0.710 |
Why?
|
| Veterans | 7 | 2017 | 904 | 0.690 |
Why?
|
| Heart Rate | 13 | 2014 | 568 | 0.670 |
Why?
|
| Trigeminal Nerve | 2 | 2022 | 22 | 0.650 |
Why?
|
| Yohimbine | 6 | 2003 | 41 | 0.640 |
Why?
|
| Mental Disorders | 8 | 2016 | 659 | 0.560 |
Why?
|
| Thyrotropin-Releasing Hormone | 10 | 1992 | 25 | 0.560 |
Why?
|
| Double-Blind Method | 39 | 2022 | 1738 | 0.540 |
Why?
|
| Depression | 7 | 2017 | 943 | 0.540 |
Why?
|
| Norepinephrine | 22 | 1998 | 276 | 0.530 |
Why?
|
| Olfactory Cortex | 1 | 2015 | 3 | 0.520 |
Why?
|
| Middle Aged | 86 | 2019 | 21147 | 0.520 |
Why?
|
| Methoxyhydroxyphenylglycol | 17 | 1998 | 41 | 0.520 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 286 | 0.510 |
Why?
|
| Dog Diseases | 5 | 1994 | 45 | 0.480 |
Why?
|
| Dogs | 11 | 1994 | 490 | 0.480 |
Why?
|
| Transcranial Direct Current Stimulation | 3 | 2022 | 111 | 0.430 |
Why?
|
| Prefrontal Cortex | 4 | 2015 | 640 | 0.430 |
Why?
|
| Mood Disorders | 10 | 2018 | 132 | 0.420 |
Why?
|
| Imipramine | 7 | 1998 | 44 | 0.400 |
Why?
|
| Hypothalamo-Hypophyseal System | 12 | 2005 | 150 | 0.390 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 5 | 2019 | 91 | 0.370 |
Why?
|
| Mutism | 3 | 1995 | 9 | 0.360 |
Why?
|
| Comorbidity | 9 | 2019 | 1426 | 0.350 |
Why?
|
| Thyrotropin | 8 | 1991 | 49 | 0.340 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2003 | 57 | 0.340 |
Why?
|
| Personality Inventory | 12 | 2003 | 197 | 0.340 |
Why?
|
| Cataplexy | 1 | 2009 | 25 | 0.330 |
Why?
|
| Circadian Rhythm | 7 | 2013 | 218 | 0.320 |
Why?
|
| Narcolepsy | 1 | 2009 | 45 | 0.320 |
Why?
|
| Blood Pressure | 11 | 2004 | 1451 | 0.320 |
Why?
|
| Risk-Taking | 1 | 2009 | 210 | 0.310 |
Why?
|
| Dexamethasone | 6 | 1994 | 150 | 0.300 |
Why?
|
| Long QT Syndrome | 2 | 2005 | 14 | 0.290 |
Why?
|
| Electroencephalography | 10 | 2015 | 418 | 0.290 |
Why?
|
| Immobility Response, Tonic | 1 | 2006 | 3 | 0.280 |
Why?
|
| Fluoxetine | 4 | 1994 | 40 | 0.280 |
Why?
|
| Freezing Reaction, Cataleptic | 1 | 2006 | 10 | 0.280 |
Why?
|
| Glutamic Acid | 1 | 2009 | 332 | 0.280 |
Why?
|
| Pituitary-Adrenal System | 8 | 1997 | 138 | 0.270 |
Why?
|
| Sleep Deprivation | 7 | 2014 | 81 | 0.270 |
Why?
|
| Hospitalization | 3 | 2011 | 978 | 0.260 |
Why?
|
| Posture | 4 | 2004 | 107 | 0.260 |
Why?
|
| Pentagastrin | 2 | 1997 | 16 | 0.260 |
Why?
|
| Diagnosis, Differential | 12 | 2009 | 1140 | 0.260 |
Why?
|
| Anti-Anxiety Agents | 5 | 2009 | 107 | 0.260 |
Why?
|
| Receptors, Adrenergic | 11 | 1988 | 68 | 0.260 |
Why?
|
| Affect | 3 | 2018 | 218 | 0.260 |
Why?
|
| Autonomic Nervous System | 2 | 2004 | 31 | 0.250 |
Why?
|
| Alprazolam | 6 | 2005 | 35 | 0.250 |
Why?
|
| Motor Activity | 4 | 2003 | 621 | 0.250 |
Why?
|
| Sensory Thresholds | 5 | 2021 | 50 | 0.250 |
Why?
|
| Human Growth Hormone | 1 | 2005 | 20 | 0.250 |
Why?
|
| Polysomnography | 3 | 2003 | 92 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2015 | 2223 | 0.240 |
Why?
|
| Linear Models | 2 | 2004 | 521 | 0.240 |
Why?
|
| Adenosine | 5 | 1994 | 165 | 0.230 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2003 | 17 | 0.230 |
Why?
|
| Paroxetine | 1 | 2004 | 28 | 0.230 |
Why?
|
| Life Change Events | 6 | 1988 | 223 | 0.230 |
Why?
|
| Prolactin | 5 | 1991 | 61 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2006 | 1745 | 0.230 |
Why?
|
| Analysis of Variance | 7 | 2010 | 1040 | 0.220 |
Why?
|
| Disease Models, Animal | 7 | 1994 | 2550 | 0.220 |
Why?
|
| Sleep, REM | 6 | 2013 | 93 | 0.220 |
Why?
|
| Reference Values | 8 | 2004 | 579 | 0.220 |
Why?
|
| Growth Hormone-Releasing Hormone | 3 | 1993 | 17 | 0.220 |
Why?
|
| Respiration | 1 | 2004 | 91 | 0.220 |
Why?
|
| Triiodothyronine | 6 | 1990 | 22 | 0.220 |
Why?
|
| Blood Platelets | 6 | 1988 | 284 | 0.210 |
Why?
|
| Self-Injurious Behavior | 1 | 2003 | 31 | 0.210 |
Why?
|
| Young Adult | 10 | 2019 | 5717 | 0.210 |
Why?
|
| Brain Mapping | 5 | 2017 | 532 | 0.200 |
Why?
|
| Behavior, Animal | 5 | 2009 | 470 | 0.200 |
Why?
|
| Homovanillic Acid | 6 | 2010 | 52 | 0.200 |
Why?
|
| Serotonin | 4 | 1994 | 144 | 0.200 |
Why?
|
| Social Adjustment | 2 | 2010 | 74 | 0.190 |
Why?
|
| Glycols | 3 | 1988 | 9 | 0.190 |
Why?
|
| Lithium | 8 | 1987 | 76 | 0.190 |
Why?
|
| Rhinitis | 2 | 2016 | 383 | 0.190 |
Why?
|
| Thyroid Function Tests | 4 | 1990 | 21 | 0.180 |
Why?
|
| Cues | 2 | 2015 | 654 | 0.180 |
Why?
|
| Brain Chemistry | 3 | 1998 | 173 | 0.180 |
Why?
|
| Behavior Therapy | 4 | 2010 | 297 | 0.180 |
Why?
|
| Sinusitis | 2 | 2016 | 432 | 0.180 |
Why?
|
| Deafness | 2 | 1994 | 64 | 0.180 |
Why?
|
| Clinical Trials as Topic | 17 | 1997 | 848 | 0.180 |
Why?
|
| Tobacco Use Disorder | 2 | 2015 | 432 | 0.180 |
Why?
|
| Brain Diseases | 1 | 2000 | 78 | 0.180 |
Why?
|
| Memory | 3 | 2015 | 214 | 0.180 |
Why?
|
| Ambulatory Care | 4 | 2019 | 340 | 0.180 |
Why?
|
| Thyroid Gland | 6 | 1994 | 67 | 0.180 |
Why?
|
| Skin | 1 | 2003 | 451 | 0.170 |
Why?
|
| Self Concept | 1 | 2000 | 132 | 0.170 |
Why?
|
| Thyroid Hormones | 3 | 1991 | 31 | 0.160 |
Why?
|
| Sleep Paralysis | 2 | 2009 | 4 | 0.160 |
Why?
|
| Antimanic Agents | 2 | 2009 | 21 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1553 | 0.150 |
Why?
|
| Olfactory Pathways | 1 | 2017 | 9 | 0.150 |
Why?
|
| Adolescent | 14 | 2021 | 8912 | 0.150 |
Why?
|
| Antidepressive Agents, Tricyclic | 6 | 1998 | 45 | 0.150 |
Why?
|
| Virtual Reality Exposure Therapy | 1 | 2017 | 7 | 0.150 |
Why?
|
| Neuropeptides | 2 | 2010 | 106 | 0.150 |
Why?
|
| Body Weight | 2 | 1992 | 554 | 0.150 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1997 | 32 | 0.150 |
Why?
|
| Cerebral Ventricles | 2 | 1988 | 36 | 0.150 |
Why?
|
| Infusions, Intravenous | 7 | 1997 | 334 | 0.150 |
Why?
|
| Olfaction Disorders | 1 | 2019 | 100 | 0.150 |
Why?
|
| Lactic Acid | 3 | 1997 | 86 | 0.150 |
Why?
|
| Social Environment | 4 | 1994 | 182 | 0.150 |
Why?
|
| Serotonin Agents | 1 | 1997 | 13 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 216 | 0.140 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 1986 | 435 | 0.140 |
Why?
|
| Sympathetic Nervous System | 3 | 1998 | 81 | 0.140 |
Why?
|
| Smoking | 2 | 2015 | 1452 | 0.140 |
Why?
|
| Students | 1 | 2018 | 233 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2019 | 402 | 0.140 |
Why?
|
| Time Factors | 9 | 2016 | 4655 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 181 | 0.140 |
Why?
|
| Otologic Surgical Procedures | 1 | 2016 | 23 | 0.130 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 35 | 0.130 |
Why?
|
| Animals | 21 | 2013 | 20881 | 0.130 |
Why?
|
| Rubber | 1 | 2015 | 13 | 0.130 |
Why?
|
| Lithium Carbonate | 5 | 2009 | 31 | 0.130 |
Why?
|
| Physical Stimulation | 1 | 2015 | 67 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2014 | 1342 | 0.130 |
Why?
|
| Memory, Episodic | 1 | 2015 | 10 | 0.130 |
Why?
|
| Hypothalamus | 2 | 2013 | 78 | 0.120 |
Why?
|
| Gray Matter | 1 | 2015 | 57 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 772 | 0.120 |
Why?
|
| Organ Size | 1 | 2015 | 242 | 0.120 |
Why?
|
| Psychotherapy | 1 | 2017 | 253 | 0.120 |
Why?
|
| Electrolytes | 2 | 1986 | 47 | 0.120 |
Why?
|
| Military Personnel | 1 | 2017 | 221 | 0.120 |
Why?
|
| Species Specificity | 3 | 1992 | 303 | 0.120 |
Why?
|
| Phototherapy | 1 | 2014 | 28 | 0.120 |
Why?
|
| Galvanic Skin Response | 1 | 2014 | 67 | 0.120 |
Why?
|
| Pain | 5 | 1988 | 472 | 0.120 |
Why?
|
| Growth Disorders | 1 | 1994 | 21 | 0.120 |
Why?
|
| Social Alienation | 1 | 1994 | 2 | 0.120 |
Why?
|
| Aged | 15 | 2019 | 14862 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 248 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2009 | 381 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2016 | 2800 | 0.120 |
Why?
|
| Substance-Related Disorders | 4 | 2019 | 1242 | 0.110 |
Why?
|
| Nonlinear Dynamics | 2 | 2004 | 55 | 0.110 |
Why?
|
| Pituitary Hormones | 2 | 2013 | 16 | 0.110 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2010 | 257 | 0.110 |
Why?
|
| Craving | 1 | 2015 | 200 | 0.110 |
Why?
|
| Attention | 2 | 2015 | 225 | 0.110 |
Why?
|
| Diazepam | 3 | 1988 | 23 | 0.110 |
Why?
|
| Affective Disorders, Psychotic | 5 | 1987 | 23 | 0.110 |
Why?
|
| Catecholamines | 2 | 1991 | 73 | 0.110 |
Why?
|
| Suicide | 1 | 2014 | 116 | 0.110 |
Why?
|
| Hypothalamic Hormones | 1 | 2013 | 13 | 0.110 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 1993 | 6 | 0.110 |
Why?
|
| Dipyridamole | 1 | 1993 | 26 | 0.110 |
Why?
|
| Melanins | 1 | 2013 | 24 | 0.110 |
Why?
|
| Tritium | 3 | 2009 | 101 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 1996 | 158 | 0.110 |
Why?
|
| Pregnancy | 2 | 2018 | 2334 | 0.110 |
Why?
|
| Defense Mechanisms | 1 | 1992 | 14 | 0.110 |
Why?
|
| Stress, Physiological | 2 | 1998 | 215 | 0.110 |
Why?
|
| Dystonia | 1 | 1992 | 18 | 0.100 |
Why?
|
| Single-Blind Method | 4 | 2015 | 249 | 0.100 |
Why?
|
| Wakefulness | 4 | 2013 | 75 | 0.100 |
Why?
|
| Receptors, Adrenergic, alpha | 8 | 1986 | 40 | 0.100 |
Why?
|
| Behavior, Addictive | 1 | 2015 | 317 | 0.100 |
Why?
|
| Receptors, Serotonin | 2 | 1991 | 74 | 0.100 |
Why?
|
| Asthma | 1 | 2016 | 345 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1992 | 110 | 0.100 |
Why?
|
| Adrenocorticotropic Hormone | 5 | 1997 | 106 | 0.100 |
Why?
|
| Adrenal Cortex | 1 | 1991 | 8 | 0.100 |
Why?
|
| Clonazepam | 2 | 1989 | 6 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 1994 | 221 | 0.100 |
Why?
|
| Benzodiazepines | 4 | 1986 | 130 | 0.100 |
Why?
|
| Nortriptyline | 1 | 1990 | 28 | 0.090 |
Why?
|
| Obsessive-Compulsive Disorder | 4 | 1987 | 88 | 0.090 |
Why?
|
| Biogenic Amines | 1 | 1990 | 15 | 0.090 |
Why?
|
| Dizziness | 1 | 1990 | 27 | 0.090 |
Why?
|
| Emotions | 3 | 2010 | 244 | 0.090 |
Why?
|
| Health Services | 1 | 2011 | 87 | 0.090 |
Why?
|
| Piperazines | 1 | 1991 | 206 | 0.090 |
Why?
|
| Nifedipine | 1 | 1990 | 40 | 0.090 |
Why?
|
| Prevalence | 2 | 2019 | 1619 | 0.090 |
Why?
|
| Premenstrual Syndrome | 1 | 1989 | 4 | 0.090 |
Why?
|
| Psychometrics | 3 | 2000 | 514 | 0.090 |
Why?
|
| Postural Balance | 1 | 1990 | 93 | 0.090 |
Why?
|
| Risk Factors | 5 | 2008 | 5731 | 0.090 |
Why?
|
| Depersonalization | 1 | 1989 | 4 | 0.090 |
Why?
|
| Hearing | 1 | 1990 | 133 | 0.090 |
Why?
|
| Maze Learning | 1 | 2009 | 138 | 0.080 |
Why?
|
| Menstrual Cycle | 1 | 1989 | 64 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 1026 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2019 | 7277 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 219 | 0.080 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1989 | 15 | 0.080 |
Why?
|
| Radioimmunoassay | 3 | 2005 | 164 | 0.080 |
Why?
|
| Neurons | 2 | 2013 | 881 | 0.080 |
Why?
|
| Placebos | 6 | 1997 | 195 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 96 | 0.080 |
Why?
|
| Health Expenditures | 1 | 2011 | 170 | 0.080 |
Why?
|
| Receptors, Purinergic | 2 | 1987 | 10 | 0.080 |
Why?
|
| Dopamine | 5 | 1994 | 474 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 346 | 0.080 |
Why?
|
| Cholesterol | 1 | 1990 | 331 | 0.080 |
Why?
|
| Verapamil | 1 | 1988 | 30 | 0.080 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 1988 | 17 | 0.080 |
Why?
|
| Thyroxine | 6 | 1988 | 62 | 0.080 |
Why?
|
| Medical Records | 1 | 1988 | 121 | 0.080 |
Why?
|
| Quality of Life | 1 | 2016 | 1515 | 0.070 |
Why?
|
| Length of Stay | 1 | 2011 | 780 | 0.070 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2000 | 8 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2009 | 2083 | 0.070 |
Why?
|
| United States | 5 | 2016 | 7367 | 0.070 |
Why?
|
| Limbic System | 4 | 1985 | 106 | 0.070 |
Why?
|
| Parkinson Disease | 2 | 1990 | 272 | 0.070 |
Why?
|
| Child | 5 | 2021 | 6405 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2000 | 2077 | 0.070 |
Why?
|
| Follow-Up Studies | 7 | 2016 | 3259 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 546 | 0.070 |
Why?
|
| Reflex, Acoustic | 1 | 2006 | 7 | 0.070 |
Why?
|
| Hormones | 2 | 1984 | 42 | 0.070 |
Why?
|
| Glucose | 5 | 1998 | 307 | 0.070 |
Why?
|
| Sympathomimetics | 1 | 2006 | 16 | 0.070 |
Why?
|
| Somatostatin | 3 | 1986 | 36 | 0.070 |
Why?
|
| Locus Coeruleus | 2 | 1984 | 55 | 0.070 |
Why?
|
| Mental Recall | 1 | 1987 | 72 | 0.070 |
Why?
|
| Reflex, Startle | 1 | 2006 | 39 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2009 | 384 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2016 | 3705 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2017 | 7029 | 0.070 |
Why?
|
| Leukopenia | 1 | 1985 | 23 | 0.070 |
Why?
|
| Nicotine | 3 | 2015 | 350 | 0.060 |
Why?
|
| Tranylcypromine | 1 | 1985 | 8 | 0.060 |
Why?
|
| Noise | 1 | 2006 | 153 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1851 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 1984 | 75 | 0.060 |
Why?
|
| Rats | 3 | 2009 | 5300 | 0.060 |
Why?
|
| Platelet Count | 1 | 1984 | 100 | 0.060 |
Why?
|
| Neural Inhibition | 1 | 2005 | 80 | 0.060 |
Why?
|
| Entropy | 1 | 2004 | 16 | 0.060 |
Why?
|
| Hydroxyindoleacetic Acid | 3 | 2010 | 36 | 0.060 |
Why?
|
| Hypoglycemia | 1 | 1984 | 72 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 80 | 0.060 |
Why?
|
| Baroreflex | 1 | 2004 | 20 | 0.060 |
Why?
|
| Epilepsy | 2 | 1985 | 336 | 0.060 |
Why?
|
| Sleep Stages | 3 | 1994 | 30 | 0.050 |
Why?
|
| Behavior | 3 | 1990 | 59 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 2 | 1986 | 290 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2016 | 1330 | 0.050 |
Why?
|
| Stress, Psychological | 2 | 2003 | 824 | 0.050 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1982 | 20 | 0.050 |
Why?
|
| Heroin Dependence | 1 | 1982 | 23 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2003 | 100 | 0.050 |
Why?
|
| Anticonvulsants | 2 | 1986 | 223 | 0.050 |
Why?
|
| Artifacts | 1 | 2003 | 125 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1983 | 131 | 0.050 |
Why?
|
| Electric Stimulation | 1 | 2022 | 218 | 0.050 |
Why?
|
| Epinephrine | 2 | 1997 | 103 | 0.050 |
Why?
|
| Social Behavior | 2 | 1992 | 164 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1988 | 2324 | 0.050 |
Why?
|
| Evoked Potentials, Auditory | 2 | 1994 | 47 | 0.050 |
Why?
|
| Functional Laterality | 3 | 1998 | 240 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 1990 | 649 | 0.050 |
Why?
|
| Cerebral Cortex | 2 | 2003 | 415 | 0.050 |
Why?
|
| Schizophrenia | 5 | 1987 | 206 | 0.040 |
Why?
|
| Phenelzine | 2 | 1991 | 7 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2000 | 161 | 0.040 |
Why?
|
| Clorgyline | 4 | 1984 | 4 | 0.040 |
Why?
|
| Antidepressive Agents | 4 | 1986 | 216 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2003 | 403 | 0.040 |
Why?
|
| Frontal Lobe | 2 | 1994 | 156 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 1990 | 567 | 0.040 |
Why?
|
| Corticotropin-Releasing Hormone | 3 | 1990 | 79 | 0.040 |
Why?
|
| Syndrome | 3 | 1990 | 255 | 0.040 |
Why?
|
| Photic Stimulation | 2 | 2013 | 229 | 0.040 |
Why?
|
| Phenotype | 2 | 1994 | 947 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2019 | 55 | 0.040 |
Why?
|
| Drug Synergism | 3 | 1990 | 260 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2018 | 18 | 0.040 |
Why?
|
| Propylamines | 3 | 1983 | 22 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2014 | 951 | 0.040 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2018 | 57 | 0.040 |
Why?
|
| Orexins | 2 | 2010 | 52 | 0.040 |
Why?
|
| Acute Disease | 2 | 1992 | 658 | 0.040 |
Why?
|
| Peripheral Nervous System | 1 | 1998 | 12 | 0.040 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 1992 | 138 | 0.040 |
Why?
|
| Child, Preschool | 2 | 1995 | 3187 | 0.040 |
Why?
|
| Recurrence | 2 | 1990 | 948 | 0.040 |
Why?
|
| Anger | 1 | 2017 | 47 | 0.040 |
Why?
|
| Universities | 1 | 2018 | 191 | 0.040 |
Why?
|
| Nervous System Diseases | 2 | 1994 | 142 | 0.040 |
Why?
|
| Temporal Lobe | 2 | 1989 | 125 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1997 | 22 | 0.040 |
Why?
|
| Ondansetron | 1 | 1997 | 13 | 0.040 |
Why?
|
| Age Factors | 2 | 1992 | 1864 | 0.040 |
Why?
|
| Buspirone | 1 | 1997 | 36 | 0.040 |
Why?
|
| Receptors, GABA-A | 3 | 1987 | 89 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 3 | 1998 | 40 | 0.030 |
Why?
|
| Alberta | 1 | 2016 | 15 | 0.030 |
Why?
|
| Electroconvulsive Therapy | 3 | 1987 | 402 | 0.030 |
Why?
|
| Psychotic Disorders | 3 | 1987 | 157 | 0.030 |
Why?
|
| Internet | 1 | 2018 | 390 | 0.030 |
Why?
|
| Opioid-Related Disorders | 1 | 1980 | 298 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 267 | 0.030 |
Why?
|
| Personality Assessment | 1 | 1995 | 71 | 0.030 |
Why?
|
| Neurosecretory Systems | 2 | 1985 | 21 | 0.030 |
Why?
|
| Hypertension | 2 | 2004 | 1535 | 0.030 |
Why?
|
| Verbal Behavior | 2 | 1992 | 27 | 0.030 |
Why?
|
| Association Learning | 1 | 2015 | 36 | 0.030 |
Why?
|
| Prognosis | 3 | 2016 | 2093 | 0.030 |
Why?
|
| Periodicity | 2 | 2005 | 43 | 0.030 |
Why?
|
| Melatonin | 2 | 1986 | 39 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1994 | 46 | 0.030 |
Why?
|
| Kinetics | 2 | 1987 | 1047 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 1994 | 29 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 260 | 0.030 |
Why?
|
| Shyness | 1 | 1994 | 10 | 0.030 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 1994 | 2 | 0.030 |
Why?
|
| Tetragastrin | 1 | 1994 | 3 | 0.030 |
Why?
|
| Receptors, Cholecystokinin | 1 | 1994 | 8 | 0.030 |
Why?
|
| Role Playing | 1 | 1994 | 4 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 1994 | 18 | 0.030 |
Why?
|
| Hallucinations | 1 | 1994 | 19 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 1994 | 60 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1997 | 705 | 0.030 |
Why?
|
| Dominance, Cerebral | 1 | 1994 | 65 | 0.030 |
Why?
|
| Pedigree | 1 | 1994 | 159 | 0.030 |
Why?
|
| Delta Rhythm | 1 | 2013 | 11 | 0.030 |
Why?
|
| Channelrhodopsins | 1 | 2013 | 7 | 0.030 |
Why?
|
| Color | 1 | 2013 | 50 | 0.030 |
Why?
|
| Organ Specificity | 2 | 1990 | 167 | 0.030 |
Why?
|
| Chest Pain | 1 | 1994 | 151 | 0.030 |
Why?
|
| Receptors, Neurotransmitter | 2 | 1983 | 31 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2013 | 98 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 208 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2013 | 204 | 0.030 |
Why?
|
| Desipramine | 1 | 1992 | 47 | 0.030 |
Why?
|
| Growth | 1 | 1992 | 17 | 0.030 |
Why?
|
| Endoscopy | 1 | 2016 | 464 | 0.030 |
Why?
|
| Monoamine Oxidase | 2 | 1982 | 26 | 0.030 |
Why?
|
| Plasmids | 1 | 2013 | 258 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 1984 | 248 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 1992 | 36 | 0.030 |
Why?
|
| Probability | 1 | 1992 | 245 | 0.030 |
Why?
|
| Lactates | 1 | 1991 | 29 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1603 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 1991 | 17 | 0.020 |
Why?
|
| Methadone | 2 | 1982 | 32 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1992 | 141 | 0.020 |
Why?
|
| Equipment Design | 1 | 1992 | 500 | 0.020 |
Why?
|
| Speech | 1 | 1992 | 118 | 0.020 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1990 | 40 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 1992 | 329 | 0.020 |
Why?
|
| Cyclic AMP | 4 | 1986 | 223 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1174 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 1992 | 295 | 0.020 |
Why?
|
| Levodopa | 1 | 1990 | 12 | 0.020 |
Why?
|
| Personality Tests | 1 | 1990 | 9 | 0.020 |
Why?
|
| Acoustic Stimulation | 2 | 2006 | 206 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2358 | 0.020 |
Why?
|
| Menstruation | 1 | 1989 | 20 | 0.020 |
Why?
|
| Pulse | 1 | 1989 | 23 | 0.020 |
Why?
|
| Sensation | 1 | 1989 | 49 | 0.020 |
Why?
|
| beta-Endorphin | 1 | 1988 | 15 | 0.020 |
Why?
|
| Kindling, Neurologic | 2 | 1986 | 24 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 1994 | 866 | 0.020 |
Why?
|
| Coffee | 2 | 1985 | 18 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1989 | 215 | 0.020 |
Why?
|
| Ejaculation | 1 | 1988 | 3 | 0.020 |
Why?
|
| Orgasm | 1 | 1988 | 3 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 1988 | 108 | 0.020 |
Why?
|
| Nonprescription Drugs | 1 | 1988 | 28 | 0.020 |
Why?
|
| Thyroid Diseases | 1 | 1988 | 33 | 0.020 |
Why?
|
| Ion Channels | 1 | 1988 | 72 | 0.020 |
Why?
|
| Brain Stem | 1 | 1988 | 46 | 0.020 |
Why?
|
| Electrocardiography | 2 | 2005 | 601 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1989 | 411 | 0.020 |
Why?
|
| Sex Factors | 2 | 1989 | 1266 | 0.020 |
Why?
|
| Physical Exertion | 1 | 1988 | 75 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2010 | 378 | 0.020 |
Why?
|
| Psychological Tests | 1 | 1987 | 96 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2007 | 47 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 2006 | 50 | 0.020 |
Why?
|
| History, 19th Century | 1 | 1987 | 95 | 0.020 |
Why?
|
| Adrenergic Fibers | 1 | 1986 | 4 | 0.020 |
Why?
|
| Population Dynamics | 1 | 1986 | 30 | 0.020 |
Why?
|
| Cerebellum | 1 | 1987 | 103 | 0.020 |
Why?
|
| Diet | 2 | 1988 | 514 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 2791 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2015 | 1034 | 0.020 |
Why?
|
| Nervous System | 1 | 1986 | 45 | 0.020 |
Why?
|
| Phenytoin | 2 | 1984 | 27 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1989 | 434 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1987 | 248 | 0.020 |
Why?
|
| Random Allocation | 1 | 1987 | 442 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 1985 | 9 | 0.020 |
Why?
|
| Valproic Acid | 2 | 1984 | 93 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1985 | 10 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1985 | 57 | 0.020 |
Why?
|
| Neurotransmitter Agents | 2 | 1983 | 102 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 1985 | 61 | 0.020 |
Why?
|
| Mitral Valve Prolapse | 1 | 1985 | 40 | 0.020 |
Why?
|
| Central Nervous System | 2 | 1984 | 107 | 0.020 |
Why?
|
| Personality | 1 | 1985 | 66 | 0.020 |
Why?
|
| Schizophrenic Psychology | 1 | 1985 | 53 | 0.020 |
Why?
|
| Neutropenia | 1 | 1985 | 72 | 0.020 |
Why?
|
| Tyramine | 2 | 1983 | 16 | 0.020 |
Why?
|
| Cocaine | 2 | 1988 | 555 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 1985 | 31 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 1988 | 1054 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1985 | 122 | 0.020 |
Why?
|
| Mice | 3 | 2013 | 8474 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1985 | 289 | 0.020 |
Why?
|
| Anemia | 1 | 1985 | 104 | 0.020 |
Why?
|
| Amphetamine | 2 | 1982 | 77 | 0.010 |
Why?
|
| Marijuana Abuse | 1 | 1988 | 251 | 0.010 |
Why?
|
| Neural Pathways | 1 | 1986 | 324 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1984 | 119 | 0.010 |
Why?
|
| Reaction Time | 1 | 1984 | 170 | 0.010 |
Why?
|
| Family | 1 | 1985 | 293 | 0.010 |
Why?
|
| Psychoanalytic Therapy | 1 | 1983 | 7 | 0.010 |
Why?
|
| Hyponatremia | 1 | 1983 | 20 | 0.010 |
Why?
|
| Oxygen | 1 | 2005 | 386 | 0.010 |
Why?
|
| Cognition | 1 | 1987 | 513 | 0.010 |
Why?
|
| Psychophysiologic Disorders | 1 | 1982 | 20 | 0.010 |
Why?
|
| Chlorpromazine | 1 | 1982 | 7 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 1982 | 99 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 1990 | 940 | 0.010 |
Why?
|
| Reserpine | 1 | 1982 | 24 | 0.010 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 1982 | 24 | 0.010 |
Why?
|
| Haloperidol | 1 | 1982 | 95 | 0.010 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1982 | 30 | 0.010 |
Why?
|
| Light | 1 | 1982 | 152 | 0.010 |
Why?
|
| Endorphins | 1 | 1981 | 32 | 0.010 |
Why?
|
| Catechol O-Methyltransferase | 1 | 1982 | 31 | 0.010 |
Why?
|
| Phenylephrine | 1 | 1981 | 61 | 0.010 |
Why?
|
| Ethanol | 1 | 1988 | 893 | 0.010 |
Why?
|
| Enkephalins | 1 | 1981 | 89 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1984 | 631 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 689 | 0.010 |
Why?
|
| Dihydroergotoxine | 3 | 1986 | 4 | 0.010 |
Why?
|
| Deoxyglucose | 2 | 1990 | 32 | 0.010 |
Why?
|
| Alcoholism | 1 | 1987 | 1109 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 1196 | 0.010 |
Why?
|
| Antipsychotic Agents | 3 | 1987 | 247 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 1990 | 81 | 0.010 |
Why?
|
| Hippocampus | 1 | 1998 | 471 | 0.010 |
Why?
|
| Exercise Test | 1 | 1994 | 242 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 1986 | 208 | 0.010 |
Why?
|
| Amygdala | 2 | 1986 | 159 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1994 | 358 | 0.010 |
Why?
|
| Anomia | 1 | 1992 | 9 | 0.010 |
Why?
|
| Receptors, Opioid | 2 | 1983 | 60 | 0.010 |
Why?
|
| Fluorine Radioisotopes | 1 | 1990 | 13 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1992 | 209 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1992 | 517 | 0.010 |
Why?
|
| Implosive Therapy | 1 | 1991 | 171 | 0.010 |
Why?
|
| Communication | 1 | 1992 | 329 | 0.010 |
Why?
|
| Research Design | 1 | 1991 | 729 | 0.000 |
Why?
|
| Semantics | 1 | 1987 | 37 | 0.000 |
Why?
|
| Normetanephrine | 1 | 1986 | 8 | 0.000 |
Why?
|
| Vanilmandelic Acid | 1 | 1986 | 6 | 0.000 |
Why?
|
| Metanephrine | 1 | 1986 | 11 | 0.000 |
Why?
|
| Judgment | 1 | 1987 | 40 | 0.000 |
Why?
|
| Probenecid | 1 | 1986 | 10 | 0.000 |
Why?
|
| Diethylcarbamazine | 1 | 1986 | 1 | 0.000 |
Why?
|
| Biochemical Phenomena | 1 | 1986 | 3 | 0.000 |
Why?
|
| Haplorhini | 1 | 1986 | 44 | 0.000 |
Why?
|
| Biochemistry | 1 | 1986 | 12 | 0.000 |
Why?
|
| Receptors, Dopamine | 1 | 1986 | 119 | 0.000 |
Why?
|
| Cats | 1 | 1986 | 292 | 0.000 |
Why?
|
| Thyroxine-Binding Proteins | 1 | 1984 | 1 | 0.000 |
Why?
|
| Adenylyl Cyclases | 1 | 1985 | 94 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1984 | 29 | 0.000 |
Why?
|
| Forecasting | 1 | 1986 | 277 | 0.000 |
Why?
|
| Anorexia Nervosa | 1 | 1985 | 52 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1984 | 47 | 0.000 |
Why?
|
| Biotransformation | 1 | 1984 | 69 | 0.000 |
Why?
|
| Seizures | 1 | 1986 | 279 | 0.000 |
Why?
|
| Fenfluramine | 1 | 1983 | 6 | 0.000 |
Why?
|
| Water-Electrolyte Balance | 1 | 1983 | 43 | 0.000 |
Why?
|
| Body Temperature Regulation | 1 | 1982 | 29 | 0.000 |
Why?
|
| Models, Neurological | 1 | 1982 | 136 | 0.000 |
Why?
|
| Radioligand Assay | 1 | 1981 | 109 | 0.000 |
Why?
|
| Hypotension, Orthostatic | 1 | 1980 | 15 | 0.000 |
Why?
|
| Platelet Aggregation | 1 | 1980 | 127 | 0.000 |
Why?
|